194,623 Shares in Pfizer Inc. $PFE Purchased by Core Capital Management & Research inc.

Posted by Francis Steltz on Sep 10th, 2026

Core Capital Management & Research inc. bought a new position in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the second quarter, Holdings Channel reports. The fund bought 194,623 shares of the biopharmaceutical company’s stock, valued at approximately $4,687,000. Pfizer accounts for 2.5% of Core Capital Management & Research inc.’s holdings, making the stock its 15th biggest position.

Several other hedge funds have also made changes to their positions in PFE. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the period. Godfrey Financial Associates Inc. purchased a new position in Pfizer in the fourth quarter worth approximately $26,000. Keb Asset Management LLC acquired a new stake in Pfizer during the second quarter worth $26,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Field & Main Bank purchased a new stake in Pfizer in the second quarter valued at $27,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s latest quarterly results exceeded expectations, with adjusted earnings of $0.77 per share versus the $0.68 consensus and revenue of $15.03 billion versus estimates of $14.40 billion. The results helped revive the stock after a prolonged downturn and reinforced management’s full-year 2026 EPS guidance of $2.80-$3.00. Why Pfizer Stock Was so Healthy in August
Positive Sentiment: Analysts point to Pfizer’s non-COVID portfolio, oncology pipeline and cost-cutting initiatives as potential growth and margin supports. These factors could help offset falling COVID product sales and extend the company’s recovery. Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
Neutral Sentiment: Pfizer will present at the Morgan Stanley Global Healthcare Conference on September 14. Chief Executive Albert Bourla’s comments could provide updates on the pipeline, capital allocation and the company’s strategy for managing patent losses. Pfizer Invites Public to Listen to Webcast
Neutral Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension product. The transaction may generate cash and streamline Pfizer’s portfolio, but its financial impact appears limited relative to Pfizer’s roughly $159 billion market value. Novartis India Acquires Pfizer Brands
Negative Sentiment: Jim Cramer selected Johnson & Johnson over Pfizer among healthcare stocks, a high-profile preference that may weigh on Pfizer’s relative appeal. Another comparison favored AbbVie as a stronger dividend-growth investment, despite Pfizer’s roughly 6% yield. Jim Cramer Picks J&J Over Pfizer

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on PFE shares. HSBC cut Pfizer from a “buy” rating to a “hold” rating and lowered their price target for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. JPMorgan Chase & Co. decreased their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, September 5th. Finally, BMO Capital Markets reduced their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.28.

Check Out Our Latest Research Report on Pfizer

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.82 on Thursday. The stock has a market capitalization of $158.58 billion, a price-to-earnings ratio of 36.61, a price-to-earnings-growth ratio of 1.87 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The business has a 50-day moving average of $26.21 and a 200 day moving average of $26.35. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $29.21.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s dividend payout ratio is presently 226.32%.

Pfizer Profile

(Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.